Daawaynta Cusub ee Isku-dhafka ah ee Dhibaatooyinka Ka-hortagga Sonkorowga ee Cornea

Siideynta Xorta ah ee HAYS | eTurboNews | eTN
Written by Linda Hohnholz

RegeneRx Biopharmaceuticals, Inc. ayaa soo tebisay in cilmi-baarayaashu ay muujiyeen waxtarka daaweynta Thymosin Beta 4 (Tβ4) oo ah daaweyn isku dhafan oo ka dhan ah hyperglycemia (sonkorowga) -isbeddelka unugyada epithelial corneal bini'aadamka.

"Daraasaddeennu waxay sharraxaysaa markii ugu horreysay in Tβ4 iyo daweynta mindhicirka mindhicirka ee vasoactive (VIP) ay door muhiim ah ka ciyaaraan nidaaminta xasilloonida isku dhafka adag iyo dib-u-habaynta cytoskeleton [kornea], kuwaas oo si dhow ula xiriira daacadnimada. Intaa waxaa dheer, Tβ4 waxay si xoog leh u dejineysaa doorkeeda daaweynta isku-dhafka ah ee cilladaha xuubka macaanka ee aan lahayn wax saameyn ah, taas oo fududeyneysa faa'iidooyinka hababka hadda ee daryeelka [indhaha], "sida laga soo xigtay kooxda cilmi-baarista.

Cilmi-baarista waxaa lagu soo bandhigay Ururka Cilmi-baarista Aragga iyo Ophthalmology (ARVO) 2022 kulanka, oo lagu qabtay May 1-4, 2022, ee Denver, Colorado. Kooxda cilmi-baarista waxaa ka mid ahaa saynisyahano iyo dhakhaatiir ka socda Jaamacadda Wayne State School of Medicine ee Detroit, MI; Jaamacadda Central Florida College of Health Professors and Sciences ee Orlando, FL; iyo Jaamacadda Mansoura ee Mansoura, Masar. Cilmi-baarista waxaa maalgeliyay Machadka Qaranka ee Caafimaadka, Xarunta Eversight ee Cilmi-baarista Bankiga Aragga iyo Indhaha, iyo Cilmi-baarista si looga hortago indho la'aanta.

MAXAA LAGU QAADAYAA MAQAALKAN:

  • “Our study elucidates for the first time that a Tβ4 and vasoactive intestinal peptide (VIP) combo treatment plays a crucial role in regulating the tight junction stability and cytoskeleton rearrangement [of the cornea], which are closely related to barrier integrity.
  • The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado.
  • is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (Tβ4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells.

War ku saabsan qoraaga

Linda Hohnholz

Tafatiraha guud ee eTurboNews ku salaysan eTN HQ.

Rukumo
Ogeysii
martida
0 Comments
Jawaabaha Gudaha ah
Eeg dhammaan faallooyinka
0
Waan jeclaan lahaa fikradahaaga, fadlan faallo ka bixi.x
()
x
La wadaag...